Ambroxol - Zywie/Belrose

Drug Profile

Ambroxol - Zywie/Belrose

Alternative Names: BEL 0218; EXR-202; EXT-202; Ziva

Latest Information Update: 12 Nov 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ExSAR
  • Developer Belrose Pharma; ExSAR; Zywie
  • Class Aniline compounds; Antibronchitics; Cyclohexylamines; Expectorants; Small molecules
  • Mechanism of Action Glucosylceramidase modulators; Protein folding stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gaucher's disease
  • New Molecular Entity No

Highest Development Phases

  • Phase I Gaucher's disease type III
  • Discontinued Gaucher's disease

Most Recent Events

  • 12 Nov 2015 Phase-I clinical trials in Gaucher's disease type III in USA (PO) before November 2015
  • 12 Nov 2015 Zywie and Belrose Pharma plan two phase II/III trials for Gaucher's disease type III in USA
  • 11 Nov 2015 Clinical trials in Gaucher's disease type III in Japan (PO) before November 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top